MV-002 is an orally available modified live biotherapeutic converting the majority of solid tumor patients refractory to immune checkpoint blockade (ICB) to responders. MV002 in combination with different ICB significantly increases the percentage of responding animals (e.g. anti-PD-L1 monotherapy, from 25-30% to 70/80% with MV-002 in translational models of solid tumor).

Therapeutic indications
Type of product
  • Phase
  • Partnering status
    Not partnered